In the News
Professor Eric Davidson Joins VivoScript Scientific Advisory Board
Costa Mesa, California – July 19, 2011 – VivoScript, Inc., a biotech company commercializing the In Vivo cell Reprogramming (IVR) technology platform, announced today that Eric H. Davidson, PhD, has joined its Scientific Advisory Board (SAB).
Dr. Davidson is a Norman Chandler Professor of Cell Biology at California Institute of Technology. Elected into the National Academy of Sciences in 1985, he is best known for his pioneering work on the role of gene regulation in development and evolution. He has made great contributions to the current understanding of animal development and evolution by elucidating and elaborating the concept of Gene Regulatory Networks (GRNs). Now Professor Davidson will play a key role in helping VivoScript expand and advance its IVR technology.
“We are honored to have Professor Davidson join our Scientific Advisory Board,” said John Bao, CEO of VivoScript. “His insights and expertise in GRNs will be invaluable to us. His addition to our SAB will greatly facilitate attainment of our goal: to develop affordable, practical, and effective therapeutics against some of the most devastating diseases based on the groundbreaking IVR technology platform.”
“I find the demonstration results that VivoScript’s novel technology has already achieved really impressive and I look forward to some stunning developments as these results are further expanded and characterized in depth,” commented Professor Davidson.
About VivoScript and the IVR Technology
Based in Orange County, California, VivoScript is an emerging biotech company established to commercialize a disruptive innovation in regenerative medicine. The new technology platform is named In Vivo Cell Reprogramming, or IVR. Using a combination of protein drugs, we can convert or reprogram one type of cells (substrate cells) to another type of cells (product cells) directly inside human bodies. For example, in one application, liver cells can be converted to beta cells to treat diabetes. IVR combines the advantages of drug-based and cell-based therapies while avoiding the shortcomings of both.
For further information, please contact:
Yong Zhu, PhD
VP, Research & Business Development